

1 **Running Title:** COVID-19 IgG Antibodies to Omicron and Delta Variants in Convalescent and  
2 Vaccinated Individuals

3 **Keywords:** Omicron; Antibody; COVID-19; SARS-CoV-2; Saliva; Diagnostics; Monitoring;

4 **Title:** Variability in SARS-Cov-2 IgG Antibody Affinity To Omicron and Delta Variants in  
5 Convalescent and Community mRNA Vaccinated Individuals

6 **Authors:**

7 Michael K. Tu, PhD<sup>1</sup>; Samantha H. Chiang, DDS<sup>2</sup>; David T.W. Wong, DMD, DMSc<sup>2,†</sup>; Charles  
8 M Strom MD, PhD<sup>1\*</sup>.

9

10 **Affiliations:**

11 <sup>1</sup> Liquid Diagnostics LLC, San Clemente, CA, USA (Tu, M.; Strom, C)

12 <sup>2</sup> UCLA School of Dentistry, Los Angeles, CA, USA (Chiang, S; Wong, D)

13 \* Corresponding Author (Liquid Diagnostics LLC, 2939 Calle Gaucho, San Clemente 92673 ;

14 Strom@liquid-dx.com ; +1 949 233 0623

15 <sup>†</sup>Funding sources: U18 TR003778, U54 HL119893 (to DTWW)

16 **Abstract**

17 The emergence of Omicron and Delta variants of SARS-CoV-2 has begun a number of  
18 discussions regarding breakthrough infection, waning immunity, need and timing for vaccine  
19 boosters and whether existing mRNA vaccines for the wildtype strain are adequate. Our work  
20 leverages a biosensor-based technique to evaluate the binding efficacy of SARS-CoV-2 S1  
21 specific salivary antibodies to the Omicron and Delta variants using a cohort of mRNA  
22 vaccinated (n=109) and convalescent (n=19) subjects. We discovered a wide range of binding  
23 efficacies to the variant strains, with a mean reduction of 60.5%, 26.7%, and 14.7% in  
24 measurable signal to the Omicron strain and 13.4%, 2.4%, and -6.4% percent mean reduction to  
25 the Delta Variant for convalescent, Pfizer, and Moderna vaccinated groups respectively. This  
26 assay may be an important tool in determining susceptibility to infection or need for booster  
27 immunization as the pandemic evolves.

28

29 **Key Points (85 characters per point)**

- 30 • AMPERIAL assay developed to quantify salivary SARS-CoV-2 S1 IgG antibodies to  
31 Omicron and Delta variants
- 32 • There was a reduction in affinity to both Delta and Omicron Variants
- 33 • The reduction in affinity was more pronounced to Omicron than for Delta Variants
- 34 • There was a significant difference between IgG affinities in Individuals vaccinated with  
35 Pfizer versus Moderna Vaccines

36

37 **INTRODUCTION**

38 As the COVID-19 epidemic continues into its third year, two major variants (first the  
39 Delta and subsequently the Omicron) have become the predominant strains in infected  
40 individuals. The two FDA approved mRNA vaccines are based on wild-type sequences of the  
41 Spike protein. With the emergence of the Omicron variant, some fully vaccinated individuals  
42 (including those who had a third booster injection) were still susceptible to COVID infection.  
43 The susceptibility to infection could be the result of waning immunity, a reduction in affinity of  
44 vaccine induced antibodies to the Omicron S1 protein, or a combination of the two. Questions  
45 regarding susceptibility to infection and long term immunity are being actively investigated (1)  
46 as well as speculation regarding the relationship between natural immunity and vaccine-induced  
47 antibody production (2).

48 Our laboratory has previously developed a non-invasive saliva-based quantitative  
49 biosensor assay for Anti-S1 IgG antibody levels to the wild-type SARS-CoV-2 using a  
50 proprietary platform called AMPERIAL™. We demonstrated that this assay is highly specific to  
51 COVID-19 infection (3) and can be used to serially monitor vaccinated patients for waning  
52 antibody levels (4). As the COVID-19 pandemic continues with a number of variants being  
53 monitored to determine their potential harm and differences in transmission rate, a major point  
54 of interest is whether existing mRNA vaccines based on the wild-type S1 sequence would  
55 remain efficacious with successive new variants.

56 The Amperial™ platform allows rapid development of quantitative assays for antibodies  
57 to SARS-CoV-2 variants. As soon as variant S1 antigen becomes available commercially, it can  
58 be immobilized in the conducting gel and used to quantify IgG levels in saliva. In the present  
59 study, we developed quantitative Amperial™ assays to both Delta and Omicron S1 antigen. We

60 then simultaneously measured IgG levels to the wild-type and Variant S1 antigens in a cohort of  
61 over 100 Pfizer or Moderna vaccinated individuals and 19 convalescent patients who contracted  
62 COVID-19 prior to the emergence of either the Delta or Omicron variants. We found a  
63 significant reduction in antibody affinity for the Delta variant and Omicron variants in all 3  
64 cohorts with affinity to Omicron more reduced than to Delta. We also found that Pfizer  
65 vaccinated individuals have a lower affinity to the Omicron variant than Moderna vaccinated  
66 individuals. Our work also indicates that antibodies derived from natural immunity have reduced  
67 reactivity to the Omicron variant relative to the wildtype or Delta variant.

## 68 **MATERIALS AND METHOD**

### 69 **SARS-CoV-2 Salivary Quantitative Antibody Assay**

70 As previously described, the Amperial® platform uses an integrated electrode and  
71 electrochemical reader system (EZLife Bio Inc, Los Angeles, CA) to read the oxidation-  
72 reduction byproduct of the antibody capture process. The detailed description of the Amperial®  
73 COVID-19 Antibody assay and the assay performance and validation have been described  
74 previously (3). We reported the utility of this assay in monitoring the kinetics of antibody  
75 response (4) using immobilized S1 subunit to the wild-type virus immobilized in a conducting  
76 gel on the surface of the gold electrode.

77 We selected the S1 antigen as the capture antibody because both the Pfizer and Moderna  
78 vaccines use mRNA coding for the S1 antigen. In our work we evaluated the difference  
79 between wildtype, omicron, and delta variants through the immobilization of the identical  
80 concentrations of Delta and Omicron S1 antigen and electrochemically measuring the captured

81 SARS-CoV-2 S1 specific antibodies present in saliva. For the delta variant, we used SARS-  
82 CoV-2 variant S1 Antigen B.1.6.617.2 (40591-V08H23 SinoBiological, Wayne, PA), a  
83 recombinant antigen that included T194, G142D, E156G, 157-158 deletion, and the L452R,  
84 T478K, D614G, 681R mutations. For the Omicron variant, we used SARS-CoV-2 variant S1  
85 Antigen B.1.1.529 (40591-V08H41), a recombinant antigen with the stated mutations of “A67V,  
86 HV69-70 deletion, T95I, G142D, VYY143-145 deletion, N211 deletion, L212I, ins214EPE,  
87 G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R,  
88 G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H”(5).

89 Equal concentrations of the wildtype, omicron, or delta S1 antigen were immobilized in  
90 separate gold electrodes (0.3 µg/well) on a 96-well electrochemical plate via an  
91 electropolymerized polypyrrole. Following coating of the SARS-CoV-2 antigen on the surface  
92 with the conducting polymer, salivary samples were diluted 1:10 in Casein/PBS and incubated  
93 on the plate for 10 minutes. Following a PBS-T wash, biotinylated anti-human IgG Fc is  
94 incubated on the plate as a secondary antibody, washed off with PBS-T, and then a horseradish  
95 peroxidase enzyme chain is incubated and washed off. The final measurement is performed by  
96 adding a H<sub>2</sub>O<sub>2</sub>/TMB solution and performing chronoamperometric measurement at -200 mV at  
97 60 seconds to measure the final electrochemical current generated by the completed assay  
98 complex. For the evaluation of SAR-CoV-2 efficacy, each experimental run consisted of wells  
99 where each sample was pipetted on a surface coated with wildtype antigen, variant antigen  
100 (Omicron or Delta antigen), and a polymer only well which was used to normalize for  
101 background effects.

## 102 **Human Subjects**

103           Research protocol and consents were approved by the Western Internal Review Board  
104 (Study #1302611). Vaccinated individuals under the age of 18 years, receiving  
105 immunosuppressive drugs, had prior COVID-19 infections, or received cancer chemotherapy,  
106 were excluded from the study.

107           Volunteers who had previously received a Pfizer (BioNTech) or Moderna for SARS-  
108 CoV-2 were consented. Subjects were issued a questionnaire collecting information about  
109 vaccination dates and vaccine type, along with questions to eliminate subjects who met  
110 exclusionary criteria. Saliva samples were collected using the Orasure® Oral Fluid Collection  
111 Device (Orasure Technologies, Bethlehem, PA). Individuals with documented COVID-19  
112 infection were also consented and samples obtained.

113           We analyzed saliva samples from a cohort of fully vaccinated individuals with Pfizer or  
114 Moderna mRNA vaccines in addition to a set of unvaccinated convalescent patients. The detailed  
115 demographics of the patients appears in table 1. The existing set of specimens is generally  
116 weighted towards the population that is 60+ years old. All samples were received prior to the  
117 emergence of the Omicron variant. We performed simultaneous analyses for SARS-CoV-2  
118 specific antibodies using identical amounts of either the wild-type or Omicron S1 protein  
119 immobilized in a conducting gel in the Amperial™ assay<sup>2,3</sup>. The percentage difference in  
120 measured current between wild-type and Omicron antigen was calculated for each individual.

121

122 **Table 1. Summary demographics of vaccinated cohort**

123

	<b>Omicron</b>	<b>Delta</b>
<b>Age</b>		
<20	0	0
20-29	3	5
30-39	8	8
40-49	13	13
50-59	7	7
60-69	39	38
70-79	35	33
≥80+	4	4
Unknown	19	19
<b>Gender</b>		
Male	51	54
Female	77	73
<b>Status</b>		
Pfizer	54	55
Moderna	55	53
Convalescent	19	19

124

125

126

127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145


## RESULTS

### Affinity to Delta and Omicron Variants

Available samples were tested using the AMPERIAL™ assay, with each plate containing a wild-type in comparison with a variant antigen (omicron or delta) for each sample. Following completion of each experiment, comparisons were calculated between the measured current of the wildtype on each plate and the variant antigen on each plate. For the omicron antigen, 55 Moderna, 54 Pfizer, and 19 convalescent samples were tested. For the delta antigen, 53 Moderna, 55 Pfizer, and 19 convalescent samples were tested. We then calculated a percent reduction using the antibody level to the wildtype minus the antibody level to the variant divided by the antibody level to the wild-type antigen. This calculation yields the percentage of reduction in affinity to the variant (Figure 1).

Analysis of the different groups showed that for the omicron variant there were reductions of 60.5%, 26.7%, and 14.7% in mean signal compared to wildtype for the convalescent, Pfizer, and Moderna samples respectively. For the delta variant, a 13.4%, 2.4%, and -6.4% percent mean reduction to the delta variant was observed for convalescent, Pfizer, and Moderna samples respectively. There was a wide variation in affinities among individuals. Many individuals had little reduction or even increased affinity to the variants, whereas others had significant reduction of 50% or more. The reductions were greatest in the convalescent patients, followed by the omicron and then the delta variants.





147


148 Figure 1. Percentage reduction relative to wildtype for samples run for Delta and Omicron  
 149 variants of SARS-CoV-2 for different categories.

150 We performed paired sample paired t-tests for each individual sample run with both the  
 151 wild-type and the variant assays. Within the Omicron variant group, statistical significance was  
 152 found between the Pfizer and Moderna vaccines ( $p=0.0042$ ), the Pfizer and Convalescent group  
 153 ( $p=2.7e-06$ ), and the Moderna and Convalescent group ( $p=1.7e-08$ ). Within the Delta variant  
 154 group, statistical significance was found between the Pfizer and Moderna vaccines ( $p=0.017$ ) and  
 155 the Moderna and Convalescent group ( $p=0.0049$ ) while there was no significance found between  
 156 the Pfizer and Convalescent group ( $p=0.18$ ).

157 For comparisons within the same category of antibodies: within the convalescent group,  
 158 statistical significance was found between the omicron and delta variants ( $p=2e-07$ ). Within the

159 Moderna group, significance was found between omicron and delta variants ( $p=5.4e-06$ ). Within  
160 the Pfizer group, significance was found between the omicron and delta variants ( $p=8e-07$ ).


161 To summarize, statistical significance was found in all cases of comparisons within  
162 variant groups and within antibody groups excluding the case between Pfizer and Convalescent  
163 antibodies for the Delta variant.



164

165 Figure 2. Within variant comparison of antibody level reduction.

166



167

168 Figure 3 Within antibody group comparison of antibody level reductions

169

170 Table 2 is summary of the percentage of individuals in each group that experience a >50%

171 reduction in antibody affinity to the variant. Of note is that in the convalescent group, 3

172 individuals (15%) had a >50% reduction in affinity to the Delta variant and 13 of 19 individuals

173 (79%) had a >50% reduction in antibody affinity to the Omicron variant. In the vaccinated

174 cohorts, 22% of Pfizer vaccinated individuals experienced a greater than 50% reduction in

175 antibody affinity to the omicron variant and 11% of Moderna vaccinated individuals had similar

176 decreases.

177

178

179 Table 2: Percentage of individuals experiencing a >50% drop in affinity to SARS-CoV-2

180 Variants

<b>Variant</b>	<b>Convalescent Individuals</b>	<b>Moderna Individuals</b>	<b>Pfizer Individuals</b>
<i>Delta</i>	3/19 (16%)	0/53 (0%)	1/55 (2%)
<i>Omicron</i>	13/19 (68%)	6/55 (11%)	12/54 (22%)

181

182

183

### **DISCUSSION**

184

The data presented demonstrate the omicron variant provides a greater risk and

185 susceptibility compared to wildtype or delta variants of SARS-CoV-2. As the experimental

186 results show, there is a significant decrease in binding affinity (14.7%-26.7%) for the Omicron

187 variant relative to the wildtype, and there are significant differences between all groups of delta

188 and omicron variants, suggesting a greater risk of susceptibility to the Omicron variant than the

189 Delta variant. The reduction in antibody affinity is highly variable among individuals. More than

190 50% show little or no reduction in affinity to the Omicron variant whereas in some groups over

191 20% experience a >50% reduction in affinity. This may explain the somewhat haphazard

192 susceptibility to COVID-19 among vaccinated individuals. Our data also demonstrate that

193 individuals vaccinated with the Moderna vaccine have lower incidences of affinity reduction to

194 the Omicron variant. There is no guarantee that the next variant will show the same differences.

195 Perhaps a “mix and match” scenario where individuals receive boosters of a brand different

196 from their original vaccine may be a possible strategy for inducing a broad range of protection.

197 In this study specifically we only evaluated the affinity of IgG antibodies to the S1

198 subunit of the spike protein of SARS-CoV-2, and consequently only serves as an evaluation of a

199 subset of the antibodies related to immunogenicity. Nevertheless, inasmuch as the S1 subunit is

200 the component coded for by the existing mRNA vaccines, the results herein presented still offer a

201 large degree of insight into the reduced efficacy of antibodies in light of the various mutations  
202 present in the variant strains.

203           There was a wide variety of antibody affinity to the omicron variant among individuals,  
204 with some having equivalent binding while others had close to a 70% reduction in binding  
205 efficacy. Although currently there is no proven method to predict susceptibility to COVID-19  
206 infection using antibody measurement, it is likely that a combination of decreasing antibody  
207 levels with decreased affinity of antibodies to the omicron variant are contributing to the current  
208 spike in COVID-19 infections among vaccinated individuals.

209           Our data suggests that as more variants emerge, a modification to the existing mRNA  
210 vaccines may be required to prevent infection and transmission. By serially measuring both  
211 antibody levels and antibody affinity we may be able to determine appropriate timing of booster  
212 vaccinations.

213           While managing a global pandemic typically involves a large variety of assessments  
214 beyond functional antibodies, this study adds to the mounting evidence that salivary antibody  
215 assessment is a non-invasive, scalable, and viable method of evaluating for the dynamics of  
216 immunity during a pandemic. Since saliva measurement can be done without the involvement of  
217 health care professionals, this platform can allow broad based testing of entire populations in  
218 order to inform decision making.

## 219 **Acknowledgments**

220 The authors wish to thank our volunteers who participated in the study.

221

222

223 **References**

- 224 1. Hall, V., S. Foulkes, F. Insalata, P. Kirwan, A. Saei, A. Atti, E. Wellington, J. Khawam, K.  
225 Munro, M. Cole, C. Tranquillini, A. Taylor-Kerr, N. Hettiarachchi, D. Calbraith, N. Sajedi, I.  
226 Milligan, Y. Themistocleous, D. Corrigan, L. Crome, L. Price, S. Stewart, E. de Lacy, C.  
227 Norman, E. Linley, A. D. Otter, A. Semper, J. Hewson, S. D’Arcangelo, M. Chand, C. S. Brown,  
228 T. Brooks, J. Islam, A. Charlett, and S. Hopkins. 2022. Protection against SARS-CoV-2 after  
229 Covid-19 Vaccination and Previous Infection. *N. Engl. J. Med.* NEJMoa2118691.
- 230 2. Yu, Y., D. Esposito, Z. Kang, J. Lu, A. T. Remaley, V. De Giorgi, L. N. Chen, K. West, and  
231 L. Cao. 2022. mRNA vaccine-induced antibodies more effective than natural immunity in  
232 neutralizing SARS-CoV-2 and its high affinity variants. *Sci. Rep.* 12: 2628.
- 233 3. Chiang, S. H., M. Tu, J. Cheng, F. Wei, F. Li, D. Chia, O. Garner, S. Chandrasekaran, R.  
234 Bender, C. M. Strom, and D. T. W. Wong. 2021. Development and validation of a quantitative,  
235 non-invasive, highly sensitive and specific, electrochemical assay for anti-SARS-CoV-2 IgG  
236 antibodies in saliva. *PLOS ONE* 16: e0251342.
- 237 4. Tu, M. K., S. H. Chiang, R. A. Bender, D. T. W. Wong, and C. M. Strom. 2022. The Kinetics  
238 of COVID-19 Vaccine Response in a Community-Vaccinated Population. *J. Immunol.*  
239 *ji2100919.*
- 240 5. SARS-CoV-2 B.1.1.529 (Omicron) Spike S1 Protein (His Tag). Sinobiological Website  
241 <https://www.sinobiological.com/recombinant-proteins/sars-cov-2-cov-spike-40591-v08h41>  
242 Accessed Feb 11<sup>th</sup>, 2022 .

243

244